Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Doesn't Support Creating Ultra-Orphan Designation

Executive Summary

Agency is already approving drugs for diseases with much smaller patient populations than the traditional rare disease, officials note.

Advertisement

Related Content

Orphan Drug Policy Changes To Be Considered Under US FDA's FY 2019 Budget Proposal
Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap
Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap
FDA's Orphan Designation Backlog Plan Focuses On Efficiency, Not Staff
Orphan Drug Pricing Heading To Negotiating Table in US?
Orphan Designation Requests To Get Slower Reviews

Topics

Advertisement
UsernamePublicRestriction

Register

PS122177

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel